Newbury Pharmaceuticals AB (NEWBRY) — Financial Flexibility Index
Newbury Pharmaceuticals AB (NEWBRY) has a Financial Flexibility Index of 0.05x as of February 2026. Free cash flow of Skr2.26 Million (operating CF Skr2.26 Million minus capex Skr0.00) represents 0% of total liabilities (Skr45.96 Million). Check NEWBRY total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Newbury Pharmaceuticals AB Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for Newbury Pharmaceuticals AB across 4 annual periods. For the full cash flow conversion analysis, see NEWBRY operating cash flow.
Annual Financial Flexibility Index for Newbury Pharmaceuticals AB (2021–2024)
Year-by-year free cash flow to debt coverage for Newbury Pharmaceuticals AB. Explore NEWBRY cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.53x | Skr-20.80 Million | Skr-23.71 Million | Skr38.95 Million | ▲ +43.8% |
| 2023 | -0.95x | Skr-22.36 Million | Skr-23.23 Million | Skr23.54 Million | ▼ -283.4% |
| 2022 | 0.52x | Skr9.40 Million | Skr-15.00 Million | Skr18.14 Million | ▼ -88.2% |
| 2021 | 4.38x | Skr19.02 Million | Skr-4.07 Million | Skr4.34 Million | — |